[HTML][HTML] Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer

X Liu, P Wang, C Zhang, Z Ma - Oncotarget, 2017 - ncbi.nlm.nih.gov
Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role
of noncoding RNA regulatory networks has been more and more reveal. EGFR has been …

EGFR signaling and autophagy dependence for growth, survival, and therapy resistance

B Jutten, K Rouschop - Cell cycle, 2014 - Taylor & Francis
The epidermal growth factor receptor (EGFR) is amplified or mutated in various human
epithelial tumors. Its expression and activation leads to cell proliferation, differentiation, and …

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

N Gül, L Babes, K Siegmund… - The Journal of …, 2014 - Am Soc Clin Investig
The use of monoclonal antibodies (mAbs) as therapeutic tools has increased dramatically in
the last decade and is now one of the mainstream strategies to treat cancer. Nonetheless, it …

Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use

RL Ferris, L Licitra, J Fayette, C Even… - Clinical Cancer …, 2019 - AACR
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …

Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma

K Okuyama, T Naruse, S Yanamoto - Journal of Experimental & Clinical …, 2023 - Springer
Current clinical and observational evidence supports the EXTREME regimen as one of the
standards of care for patients with recurrent or metastatic head and neck squamous cell …

Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole–imidazole polyamide conjugate

K Hiraoka, T Inoue, RD Taylor, T Watanabe… - Nature …, 2015 - nature.com
Despite extensive efforts to target mutated RAS proteins, anticancer agents capable of
selectively killing tumour cells harbouring KRAS mutations have remained unavailable …

HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target

E Capone, T Tryggvason, I Cela, B Dufrusine… - Cell Death …, 2023 - nature.com
HER-3 (also known as ErbB-3) is a human epidermal growth factor receptor tyrosine kinases
family member, and its expression in CRC (colorectal cancer) tissues was previously …

Synonymous variants: necessary nuance in our understanding of cancer drivers and treatment outcomes

NM Kaissarian, D Meyer… - Journal Of The National …, 2022 - academic.oup.com
Once called “silent mutations” and assumed to have no effect on protein structure and
function, synonymous variants are now recognized to be drivers for some cancers. There …

Mechanisms and antitumor activity of a binary EGFR/DNA–targeting strategy overcomes resistance of glioblastoma stem cells to temozolomide

Z Sharifi, B Abdulkarim, B Meehan, J Rak, P Daniel… - Clinical Cancer …, 2019 - AACR
Purpose: Glioblastoma (GBM) is a fatal primary malignant brain tumor. GBM stem cells
(GSC) contribute to resistance to the DNA-damaging chemotherapy, temozolomide. The …

Emerging roles of microRNAs in EGFR‐targeted therapies for lung cancer

F Han, J He, F Li, J Yang, J Wei… - BioMed research …, 2015 - Wiley Online Library
Lung cancer is a leading cause of cancer mortality worldwide. Several molecular pathways
underlying mechanisms of this disease have been partly elucidated, among which the …